Skip to content

Other, net at other companies

Guardant Health logo
Guardant HealthGH
Quest Diagnostics logo
Quest DiagnosticsDGX
Charles River Laboratories logo
Charles River LaboratoriesCRL

Other financials

Income statement

See full
Revenue$25.6M+42.3%
Operating income-$6.2M+32.1%
Net income-$7.8M+29.8%
EPS (diluted)-$0.81+46.7%

Balance sheet

See full
Cash & equivalents$25.6M+45.3%
Total debt$71.6M+15.0%
Total equity$9.1M-17.4%
Total assets$94.6M+9.7%

Cash flow

See full
Operating cash flow-$10.2M-18.2%
CapEx$81.0K+9.5%
Free cash flow-$10.2M-18.1%

Valuation

See full
Market cap$233.52M+476%
Enterprise value$279.56M+204%
P/S2.4×+1.9×

Profitability

See full
Operating margin-26%-7.5pp
Net margin-33.3%-9.3pp
FCF margin-26.8%-9.6pp

Returns & leverage

See full
Return on equity-316.5%
Debt / equity7.8×+2.2×
Current ratio2.8×+0.6×

Where this comes from

Reported directly by Biodesix, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromPaymentsForOtherFinancingActivities.

The official record: Biodesix, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biodesix, Inc.'s other, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biodesix, Inc.'s other, net?
Biodesix, Inc. (BDSX) reported other, net of -$158K in Q1 2026.
How has Biodesix, Inc.'s other, net changed year-over-year?
Biodesix, Inc.'s other, net increased by 20.2% year-over-year, from -$198K to -$158K.
What is the long-term trend for Biodesix, Inc.'s other, net?
Over 3 years (2022 to 2025), Biodesix, Inc.'s other, net has grown at a 191.5% compound annual growth rate (CAGR), from -$33K to -$817K.
What does other, net mean?
Includes miscellaneous cash flows related to financing activities that are not categorized as debt issuance, dividends, or share repurchases. This may include changes in non-controlling interests, debt issuance costs, or other unique financing-related transactions. It provides a comprehensive view of non-standard financing cash movements.